| 货号 | 6004/50 |
| 别名 | 6-(2,5-Dimethoxyphenyl)-3,4-dihydro |
| 供应商 | Tocris |
| 生物活性 | Selective myeloperoxidase (MPO) inhibitor (IC50 = 1.5 μM in LPS-stimulated human whole blood). Selective for MPO over a panel of 50 receptors, enzymes, ion channels and transporters, including thyroid peroxidase. Inhibits MPO activity in peritoneal lavage and plasma in a murine peritonitis model. Also reduces lung edema in a murine pulmonary immune complex vasculitis model. Orally bioavailable. |
| 运输条件 | Ambient |
| 存放说明 | Ambient |
| 纯度 | >98 % |
| 计算分子量 | 321.35 |
| 分子式 | C14H15N3O4 |
| 可溶性/溶解性 | Soluble to 20 mM in DMSO with gentle warming |
| 参考文献 | Ruggeriet al (2015) Discovery of 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases. J.Med.Chem. 58 8513. PMID: 26509551. Zhenget al (2015) PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. J.Pharmacol.Exp.Ther. 353 288. PMID: 25698787. |